ComparativeIn VitroActivity of PH-027 Versus Linezolid and Other Anti-Anaerobic Antimicrobials Against Clinical Isolates ofClostridium difficileand Other Anaerobic Bacteria
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 15 (2) , 113-117
- https://doi.org/10.1179/joc.2003.15.2.113
Abstract
PH-027 is a new 5-triazole oxazolidinone synthesized in our laboratories, which shows strong activity against gram-positive aerobic bacteria including clinical isolates. The objective of this study was to investigate the in vitro activity of this compound in comparison with linezolid and other antibiotics against gram-positive and gram-negative anaerobes. The in vitro activity of PH-027 in comparison with those of linezolid and other antimicrobial agents was evaluated against 201 clinical isolates of gram-positive and gram-negative anaerobic bacteria by agar dilution and Etest methods. PH-027 showed excellent activity, with minimum inhibitory concentrations (MIC) in the range of 0.12-4.0 microg/ml against all isolates; MIC90s being 4.0, 1.0, 2.0, 2.0 and 2.0 microg/ml against Clostridium difficile, Peptostreptococcus spp., Bacteroides fragilis, Prevotella bivia and Fusobacterium spp. respectively. In comparison, linezolid had MIC in the range of 0.5-4.0 microg/ml against all isolates, with MIC90s of 2.0, 4.0, 4.0, 4.0 and 2.0 microg/ml against the same set of bacteria respectively. PH-027 demonstrated excellent in vitro activity that is superior to linezolid against Peptostreptococcus spp., B. fragilis and P. bivia. However, against C. difficile and Fusobacterium spp, PH-027 and linezolid showed comparable in vitro activity. Against all anaerobes, metronidazole, PH-027 and, to a lesser extent, linezolid had the most potent activity. From the results of in vitro susceptibility testing, both linezolid and PH-027 show promise in the treatment of anaerobic infections.Keywords
This publication has 12 references indexed in Scilit:
- Synthesis and antibacterial activity of 5-substituted oxazolidinonesBioorganic & Medicinal Chemistry, 2002
- In Vitro Activity of Linezolid against Clostridium difficileAntimicrobial Agents and Chemotherapy, 2002
- Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolidThe Lancet, 2001
- ANTISTAPHYLOCOCCAL (MSSA, MRSA, MSSE, MRSE) ANTIBIOTICSMedical Clinics of North America, 2001
- LinezolidDrugs, 2001
- Emerging Therapies for Serious Gram-Positive Bacterial Infections: A Focus on LinezolidClinical Infectious Diseases, 2000
- In vitro activity of linezolid and eperezolid against anaerobic bacteriaClinical Microbiology & Infection, 1999
- Susceptibility of 497 Clinical Isolates of Gram-Negative Anaerobes to Trovafloxacin and Eight Other AntibioticsJournal of Chemotherapy, 1999
- Beta-lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- In vitro susceptibility of clinical isolates ofBacteroides fragilis andBacteroides thetaiotaomicron in JapanEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992